Pharmacist-led Transitions of Care in the Outpatient Oncology Infusion Center for Patients With Solid Tumor

Thomas Jefferson University

Status: Completed

Conditions: Malignant Solid Neoplasm

Treatments: Other: Medical Chart Review; Other: Survey Administration; Other: Educational Intervention

Study type: Interventional

Funder types: Other

Identifiers

NCT04122118

19D.411

JT 13521 (Other Identifier)

Details and patient eligibility

About

This trial studies how well pharmacist-led transitions of care works in the outpatient oncology infusion center for patients with solid tumor. Having a pharmacist in the outpatient oncology infusion center may help to identify and correct medical related problems and improve overall patient and staff satisfaction. Patients receiving education may benefit from gaining a better understanding of their antineoplastic therapy. Understanding the side effects associated with the therapy may also help patients better be prepared to manage any adverse effects they may experience.

Full description

PRIMARY OBJECTIVE:

I. To demonstrate the effectiveness of a clinical oncology pharmacist in the outpatient infusion center through education, and the identification and correction of medication related problem (MRP)s.

SECONDARY OBJECTIVE:

I. To evaluate overall patient and staff satisfaction with the added clinical oncology pharmacy education.

EXPLORATORY OBJECTIVE:

I. Estimate the cost avoidance utilizing the pharmacy services provided in the prospective trial.

OUTLINE:

PHASE I: Patients' medical records are reviewed.

PHASE II: Patients receive pharmacist-led education on antineoplastic therapies including what to expect during infusion, general drug facts, common adverse effects, side effect management, and when to contact provider.

After completion of study, patients are followed up periodically.

Enrollment: 26 patients

Sex: All

Ages: 18 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Solid tumor diagnosis
• Starting day 1 of new antineoplastic infusion
• English speaking (and/or English-speaking primary caregiver/proxy)

Exclusion criteria

• Metastasis to the brain and/or central nervous system (CNS) with evidence of impaired cognition
• Severe cognitive impairment including dementia with inability to consent to the study

Trial design

Primary purpose: Health Services Research

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

26 participants in 1 patient group

Hearth services research (pharmacist-led education)

Experimental group

Description:

PHASE I: Patients' medical records are reviewed. PHASE II: Patients receive pharmacist-led education on antineoplastic therapies including what to expect during infusion, general drug facts, common adverse effects, side effect management, and when to contact provider.

Treatment:

Other: Survey Administration

Other: Educational Intervention

Other: Medical Chart Review